Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...
Fierce Biotech6d
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
BioSpace4d
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...
pharmaphorum1d
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...
pharmaphorum6d
Novo Nordisk looks east for another obesity therapy
Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which combines semaglutide with dual amylin and calcitonin receptor agonist ...
Insider Monkey3d
12 Best ADR Stocks to Buy According to Hedge Funds
In R&D developments, the company had several significant obesity treatment readouts, including CagriSema, semaglutide 7.2 milligram, and amycretin. Looking ahead to 2025, Novo Nordisk A/S (NYSE ...
Insider Monkey5d
10 Best Beaten Down Stocks to Buy According to Analysts
The company completed the acquisition of the 3 Catalent sites, and during FY 2024, it progressed its R&D pipeline, including obesity projects like CagriSema and amycretin. In 2025, Novo Nordisk A ...